## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.11 indicates fundamental undervaluation. Quality metrics strong (ROE 62%). Caution: momentum weakening (-1.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($110.98)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Wedge Capital Management L L P NC Has $33.34 Million Position in DaVita Inc. $DVA**
- Source: MarketBeat | 20251221T123504 | Somewhat-Bearish | Relevance: 100%
- Wedge Capital Management L L P NC recently trimmed its stake in DaVita Inc. (NYSE:DVA) by 6.5% during the third quarter, reducing its holdings to 250,918 shares valued at $33.34 million. Despite DaVita missing its quarterly EPS consensus, institutional investors collectively own 90.12% of the company's stock, with several firms increasing their positions. Analysts currently have a "Hold" rating on DaVita with an average price target of $148.00.

**2. Zacks Industry Outlook Highlights Encompass Health, DaVita, Option Care Health and The Pennant**
- Source: TradingView â€” Track All Markets | 20251222T140823 | Somewhat-Bullish | Relevance: 94%
- The Zacks Medical - Outpatient and Home Healthcare industry is experiencing a rapid shift towards digital healthcare delivery, driven by an aging population, cost-effectiveness, and the increasing role of AI and technological advancements. The global home healthcare market is projected to reach $747.70 billion by 2030, presenting significant opportunities for companies like Encompass Health, DaVita, Option Care Health, and The Pennant Group, despite challenges like staffing shortages. These four companies are highlighted as promising investments based on their recent performance and market outlook.

**3. Is Boston Scientific (BSX) One of the Best Healthcare AI Stocks to Buy Now?**
- Source: Finviz | 20251223T010913 | Neutral | Relevance: 60%
- TD Cowen has reaffirmed a Buy rating on Boston Scientific (BSX), naming it their "Best Idea for 2026" due to its strong growth story in the medical devices sector. The firm expects over 10% organic sales growth annually and double-digit EPS growth, driven by key products like Farapulse and Watchman. Boston Scientific also leverages AI in its medical devices to enhance imaging, predictive analytics, and remote monitoring.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $55M sold (3 transactions in 90 days).
3. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
4. Long-term trend broken: trading 13.9% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.11 suggests fair value with growth premium. Forward P/E 9.1x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.3B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.11 |
| Forward P/E | 9.1 |
| Current P/E | 10.9 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.4% to -2.3% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 42. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.28% (CS: 24) | Weak |
| RSI_14 | 42.3 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.960x | Below |
| vs SMA200 | 0.861x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $116.50
- **Stop Loss:** $110.98 (4.7% risk)
- **Target:** $127.54 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 217
- **Position Value:** $25,280.50
- **Portfolio %:** 25.28%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*